LLY Share Price | Eli Lilly & Co. Stock Analysis & Recommendation

Q: How big is Eli Lilly & Co.?

Market Cap: As of Jun 18, Eli Lilly & Co. has a market capitalization of 750,252.66 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Eli Lilly & Co. reported net sales of 49,003.20 million and a net profit of 11,106.40 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 14,192.10 million, while total assets were reported at 78,714.90 million.

Q: What does Eli Lilly & Co. do?

Overview:Eli Lilly and Company is engaged in the drug manufacturing business, specializing in pharmaceuticals and biotechnology, and operates within the large-cap market segment.Financial Snapshot:Most recent Net Sales: 12,728 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2,759 Million (Quarterly Results - Mar 2025) Market cap: USD 750,252.66 Million (Large Cap)Key Metrics:P/E: 47.00 Debt Equity: 2.24 Return on Equity: 97.65% Price to Book: 47.59 Contact Details:Address: Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001 Tel: 1 317 2762000 Website: https://www.lilly.com/

Q: Is Eli Lilly & Co. overvalued or undervalued?

As of 12 September 2025, Eli Lilly & Co. has moved from fair to expensive in its valuation grade. The company is currently considered overvalued, as indicated by its high P/E ratio of 47, a Price to Book Value of 46.31, and an EV to EBITDA of 35.51. In comparison, peers such as Johnson & Johnson have a P/E of 26.18, and AbbVie, Inc. has a P/E of 25.28, highlighting Eli Lilly's premium valuation relative to its industry.Despite a strong ROE of 97.65% and a PEG ratio of 0.87, which suggests growth potential, the valuation ratios indicate that the stock is priced significantly higher than its peers. Additionally, while Eli Lilly has outperformed the S&P 500 over the 3-year and 5-year periods with returns of 146.99% and 394.86% respectively, it has lagged in the 1-year and year-to-date comparisons, with returns of -15.70% and -1.17%. This performance underscores the concerns regarding its current valuation amidst a broader market context.

Q: Is Eli Lilly & Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Eli Lilly & Co. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands are bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a mildly bearish stance. Dow Theory shows a mildly bullish trend in both weekly and monthly perspectives. Eli Lilly has outperformed the S&P 500 across multiple periods, with a 1-week return of 9.73% compared to 0.71% for the S&P 500, and a 3-year return of 150.74% versus 76.66%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.66 M

Shareholding (Dec 2025)

FII

13.10%

Held by 795 FIIs

DII

47.76%

Held by 112 DIIs

Promoter

10.22%

How big is Eli Lilly & Co.?

22-Jun-2025

As of Jun 18, Eli Lilly & Co. has a market capitalization of approximately $750.25 billion, with recent net sales of $49.00 billion and a net profit of $11.11 billion over the last four quarters.

View full answer

What does Eli Lilly & Co. do?

22-Jun-2025

Eli Lilly and Company is a large-cap pharmaceutical and biotechnology firm specializing in drug manufacturing. As of March 2025, it reported net sales of $12.73 billion and a net profit of $2.76 billion.

View full answer

Who are in the management team of Eli Lilly & Co.?

22-Jun-2025

As of March 2022, the management team of Eli Lilly & Co. includes David Ricks as Chairman, President, and CEO, with Juan Luciano as Lead Independent Director and Independent Directors Raul Alvarez, Katherine Baicker, Carolyn Bertozzi, and Michael Eskew.

View full answer

Is Eli Lilly & Co. overvalued or undervalued?

20-Sep-2025

As of September 12, 2025, Eli Lilly & Co. is considered overvalued with a high P/E ratio of 47 and other premium valuation metrics compared to peers, despite strong growth indicators and past outperformance of the S&P 500.

View full answer

Is Eli Lilly & Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Eli Lilly & Co. shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite a mildly bearish monthly MACD and daily moving averages, while outperforming the S&P 500 in both short and long-term returns.

View full answer

Compare Eli Lilly & Co. with Similar Stocks

Johnson & Johnson AbbVie, Inc.Merck & Co., Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 33.55%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.74

Healthy long term growth as Net Sales has grown by an annual rate of 18.34%

With a growth in Net Profit of 105.14%, the company declared Very Positive results in Jun 25

With ROCE of 38.63%, it has a expensive valuation with a 14.99 Enterprise value to Capital Employed

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 952,806 Million (Large Cap)

P/E

45.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.34

Return on Equity

86.28%

Price to Book

35.91

Revenue and Profits:

Net Sales:

19,292 Million

(Quarterly Results - Dec 2025)

Net Profit:

6,636 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.78%

6 Months

32.7%

1 Year

20.68%

2 Years

31.39%

3 Years

217.87%

4 Years

276.42%

5 Years

387.39%

Eli Lilly & Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

21.58%

EBIT Growth (5y)

34.09%

EBIT to Interest (avg)

21.74

Debt to EBITDA (avg)

1.64

Net Debt to Equity (avg)

2.24

Sales to Capital Employed (avg)

0.93

Tax Ratio

18.34%

Dividend Payout Ratio

26.14%

Pledged Shares

Institutional Holding

83.35%

ROCE (avg)

33.55%

ROE (avg)

83.66%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

41.92

EV to EBIT

35.76

EV to EBITDA

32.98

EV to Capital Employed

14.69

EV to Sales

15.07

PEG Ratio

0.94

Dividend Yield

0.00%

ROCE (Latest)

41.07%

ROE (Latest)

93.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 290 Schemes (28.89%)

Foreign Institutions

Held by 795 Foreign Institutions (13.1%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 9.61% vs 13.13% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 18.87% vs -1.38% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19,292.00",
          "val2": "17,600.80",
          "chgp": "9.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9,571.70",
          "val2": "8,856.10",
          "chgp": "8.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "123.00",
          "val2": "179.60",
          "chgp": "-31.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-633.60",
          "val2": "-1,190.70",
          "chgp": "46.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,636.00",
          "val2": "5,582.50",
          "chgp": "18.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "465.80%",
          "val2": "476.50%",
          "chgp": "-1.07%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 44.70% vs 32.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 94.90% vs 102.08% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65,179.00",
          "val2": "45,042.70",
          "chgp": "44.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "31,693.00",
          "val2": "18,806.60",
          "chgp": "68.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "780.60",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3,883.00",
          "val2": "-4,522.30",
          "chgp": "14.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20,640.00",
          "val2": "10,590.00",
          "chgp": "94.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "455.60%",
          "val2": "378.30%",
          "chgp": "7.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

19,292.00

17,600.80

9.61%

Operating Profit (PBDIT) excl Other Income

9,571.70

8,856.10

8.08%

Interest

123.00

179.60

-31.51%

Exceptional Items

-633.60

-1,190.70

46.79%

Consolidate Net Profit

6,636.00

5,582.50

18.87%

Operating Profit Margin (Excl OI)

465.80%

476.50%

-1.07%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 9.61% vs 13.13% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 18.87% vs -1.38% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

65,179.00

45,042.70

44.70%

Operating Profit (PBDIT) excl Other Income

31,693.00

18,806.60

68.52%

Interest

0.00

780.60

-100.00%

Exceptional Items

-3,883.00

-4,522.30

14.14%

Consolidate Net Profit

20,640.00

10,590.00

94.90%

Operating Profit Margin (Excl OI)

455.60%

378.30%

7.73%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 44.70% vs 32.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 94.90% vs 102.08% in Dec 2024

All Annual Results

Company CV

About Eli Lilly & Co.

Eli Lilly & Co.

Pharmaceuticals & Biotechnology

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Company Coordinates

Company Details

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr INDIANAPOLIS IN : 46285-0001

Tel: 1 317 2762000

https://www.lilly.com/

Registrar Details